Exhibit 99.1
FOR IMMEDIATE RELEASE
---------------------
CONTACT: STEVEN T. SOBIESKI
CHIEF FINANCIAL OFFICER
LIFECELL CORPORATION
908-947-1100
LIFECELL ANNOUNCES SETTLEMENT OF INAMED LITIGATION
Branchburg, NJ (September 25, 2000): LifeCell Corporation (Nasdaq: LIFC)
today announced it entered into a settlement agreement for a previously
announced lawsuit filed by Inamed Corporation against LifeCell and its
co-promotion partner, Obagi Medical Products. The lawsuit alleged that LifeCell
and Obagi disseminated false advertisements with respect to the marketing of
LifeCell's Cymetra' product. All parties desired to settle and compromise the
allegations asserted by Inamed without the necessity of further expense or
litigation. LifeCell was prepared to defend its advertising claims in the court
system, but decided to enter into the settlement in order to avoid the expense
and distraction associated with litigation.
Under the terms of the settlement agreement, LifeCell and Obagi agreed to
discontinue certain comparative marketing and promotion statements on the use of
Cymetra for the reconstruction of soft tissue deficits. LifeCell and Obagi also
agreed to jointly make settlement payments to Inamed totaling $300,000 over an
eighteen-month period. The settlement allows LifeCell and Obagi to revise the
marketing and promotion statements for Cymetra commencing in January 2001, as
additional scientific data on the use of Cymetra is accumulated.
Paul Thomas, LifeCell's President and CEO stated, "We are pleased with the
expeditious settlement of the Inamed litigation. Cymetra is a major advance for
the reconstruction of soft tissue deficits and we are encouraged by the feedback
from the medical community on its use to date."
LifeCell Corporation is a leader in the emerging field of regenerative
medicine engaged in developing and marketing biologic solutions for the repair,
replacement and preservation of human tissues. LifeCell currently markets three
products based on its tissue matrix technology: AlloDerm for the plastic
reconstructive and burn markets through LifeCell's direct sales force and for
the dental market through BioHorizons Implant Systems; Cymetra' for the plastic
reconstructive and dermatology markets through LifeCell's direct sales force and
a co-promotion agreement with Obagi Medical Products; and Repliform' for the
urogynecology market through Boston Scientific Corporation. The Company's
product development programs include a small diameter vascular graft as an
alternative to autografted blood vessels, orthopedic applications of its
acellular dermal matrix and Thrombosol', a formulation for extended storage of
platelets.
Certain of the statements contained in this news release are
"forward-looking statements" (as defined in the Private Securities Litigation
Reform Act of 1995). While these statements reflect the Company's current
beliefs and are based on assumptions that the Company believes are reasonable,
they are subject to uncertainties and risks that could cause actual results to
differ materially from anticipated results. These risk factors include, but are
not limited to, the uncertainty of product development, of clinical trials, of
regulatory approval and patent protection, the demand for our products and
services, the outcome of pending litigation, economic conditions and product and
other risks as detailed in the Company's reports filed with the Securities and
Exchange Commission.
<PAGE>
